CryoLife sets up drug delivery subsidiary:
This article was originally published in Clinica
CryoLife is to form a separate subsidiary, AuraZyme Pharmaceuticals, to concentrate on the commercial development of light-activated drug delivery systems. The company says potential applications for the system include the treatment of cancer, heart attack, stroke and bloodclots. Atlanta, Georgia-based CryoLife develops tissue-engineered implantable heart valves, vascular grafts and protein-based surgical adhesives.